- Home
- / Xilio Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Xilio Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1
2024-10-29
Market Capitalization
$43.5 M
2024-10-29
Revenue
$43.8 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 6.3M | 43.8M | |||
| General and administrative expense | 23.9M | 29.9M | 27.0M | 24.8M | 29.7M |
| Operating expense total | 89.1M | 66.0M | 85.7M | ||
| EBIT | (75.0M) | (89.1M) | (79.1M) | (60.6M) | (42.0M) |
| EBIT margin, % | -954.9% | -95.9% | |||
| Interest expense | 573.0K | 62.0K | |||
| Pre tax profit | (35.0M) | ||||
| Net Income | (75.8M) | (88.2M) | (76.4M) | (58.2M) | (35.0M) |
| EPS | (3.2) | (2.0) | (1.1) | (4.2) |